BioCatalytics expands enzyme product range and reach

Published: 12-Oct-2006
Ingredients

California-based enzyme developer BioCatalytics has agreed a distribution and product development deal with Novozymes, of Denmark, as well as a technology agreement with Ciba Specialty Chemicals, of Basel, Switzerland.


California-based enzyme developer BioCatalytics has agreed a distribution and product development deal with Novozymes, of Denmark, as well as a technology agreement with Ciba Specialty Chemicals, of Basel, Switzerland.

Novozymes is a leading manufacturer of industrial enzymes, many of which can provide a more environmentally friendly means of producing pharmaceutical compounds and intermediates. This deal enables BioCatalytics to offer a broadened range of enzymes for chiral synthesis applications, including new enzymes not previously available for chemical synthesis.

Under the agreement, BioCatalytics will contribute the formulation and r&d expertise, while Novozymes will handle the manufacturing of commercial quantities.

BioCatalytics has already developed novel biocatalysts and patented methods for the production of a range of pharmaceutical intermediates, including non-natural amino acids, beta-amino acids, chiral alcohols, carboxylic acids, esters, and other chiral materials.

'This agreement allows Novozymes to expand its product offerings in the rapidly growing biocatalysis field,' said Hans Christian Holm, senior manager for Novozymes in Bagsvaerd, Denmark. 'As a world-leading company in this area, BioCatalytics is ideally suited to develop new markets for Novozymes' products in chemical synthesis applications.'

Meanwhile, BioCatalytics has also entered into a new technology agreement with Ciba Specialty Chemicals that will lead to the development of new, more stable enzymes for use in ketone reduction chemistry. Ketoreductases are useful for enantiomeric resolutions, chemo- and regioselective reductions/oxidations, and synthesis of chiral alcohols from ketones, ketoacids, and ketoesters. They also catalyse the reduction of a number of aldehydes. These enzymes are stereoselective and exhibit a very broad substrate range.

The deal gives BioCatalytics the exclusive rights to the Rhodococcus ruber alcohol dehydrogenase (ADH) enzyme, an exceptionally solvent-stable enzyme not previously commercially available.

See more

You may also like

Ingredients

Novozymes reports a good year in 2014

Read more
Sales of enzyme solutions and albumin for the manufacture and formulation of pharma ingredients up by 10%

Trending Articles

  1. FDA makes groundbreaking decision to waive clinical efficiency studies for monoclonal antibody biosimilars The University of Illinois secured the first-ever FDA acceptance to waive clinical efficiency studies (CESs) for the biological drugs
  2. Rousselot Rousselot is a global leader of gelatin and collagen-based solutions, serving the food, health & nutrition, biomedical, and pharmaceutical sectors. With our advanced Science & Innovation team, we unlock the secrets of the collagen molecule to create products that meet the highest standards of safety and quality. Through our state-of-the-art operations and extensive technical and formulation expertise, we help our customers achieve their goals, create world-class products, and we “Reach further together”. Rousselot is Darling’s Ingredients Health Brand.
  3. Debunking the myths of HPMC adoption Adopting new products, formulations and ways of working can be a challenge for industries as regulated as pharmaceuticals, writes Dr Subhashis Chakraborty, General Manager, Head of Global Product Management, at ACG Capsules
  4. Lubrizol to showcase game-changing excipients and nutraceutical ingredients at CPHI Frankfurt Lubrizol partners with pharmaceutical and nutraceutical companies to develop innovative solutions that improve patient outcomes and offer consumer benefits
  5. Evonik increases plant-derived cholesterol supply The ingredient is used in the manufacture of mRNA vaccines and gene therapies

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Ingredients

Novozymes reports a good year in 2014

Sales of enzyme solutions and albumin for the manufacture and formulation of pharma ingredients up by 10%
Ingredients

Good outlook for Novozymes after eventful 2013

Strong increase in sales of products for the manufacture of pharmaceuticals
Ingredients

Novozymes’ agreement with GSK brings payback closer

GSK is seeking approval in Europe for diabetes drug Eperzan
You need to be a subscriber to read this article.
Click here to find out more.
Ingredients

Safe, consistent and sustainable hyaluronic acid

Hyaluronic acid (HA) is a naturally occurring polysaccharide ubiquitous in nature, which is distributed widely throughout connective, epithelial and neural tissues in the human body. Due to its intrinsic biocompatibility, biodegradability and diverse biological functions, HA is widely used in medical devices and pharmaceutical applications. In response to concerns surrounding the purity of many sources of HA, a <i>Bacillus subtilis</i>-based fermentation process has been developed by Novozymes Biopharma.
Ingredients

Novozymes Biopharma aligns recombinant human albumin portfolio with new brand name

Portfolio will bring together rAlbumin product line with introduction of new brand names Recombumin Alpha and Recombumin Prime
Ingredients

Enzymes cut industrial emissions and resource use

Comprehensive scientific review of existing studies shows enzyme technology is a promising means of moving towards cleaner industrial production
You need to be a subscriber to read this article.
Click here to find out more.
Ingredients

Let enzymes do the work

The use of enzyme catalysts has had a real impact on the synthesis of pharmaceutical ingredients, making it possible to improve some syntheses dramatically and even make some molecules that would otherwise be either impossible or impractical to synthesise. The use of flow reactors in biocatalysis faces challenges arising from the heterogeneous slurry nature of the reaction mixture and problems with gas and liquid handling. But research is being carried out into continuous manufacturing methods for biocatalytic reactions.
Subscribe now